03 Dec 2013 Posted in News Release By Press Office
Jonathan will commence his appointment following the ABPI’s AGM in April 2014, when he will take over from current President, Deepak Khanna, Senior Vice President and MSD UK Managing Director. Jonathan will serve for one year with the option of standing for re-election for a further year.
Jonathan began his career at Glaxo before joining Pfizer in 1999. In January 2012, he took up the role of UK Managing Director. Previous to this, Jonathan held a number of roles across Pfizer, including spending six years in France establishing European regional teams and serving as Marketing Head for the European Specialty Asset Teams. Jonathan is a member of the ABPI Board of Management.
Prior to Jonathan taking over the Presidency in April, Deepak will continue to lead the organisation, working on initially embedding the new voluntary pricing scheme, which begins on 1 January 2014 and handing over a successful term to Jonathan.
Looking ahead to his appointment next year, Jonathan Emms said:
“I am immensely proud to work in an industry which makes such a positive difference to the health of millions of people both in the UK and around the world. It is an honour to be elected as President of the ABPI from April 2014 and to lead our industry at such a crucial time.”
Commenting on Jonathan’s appointment, Stephen Whitehead, Chief Executive of the ABPI, said:
“I am very much looking forward to working with Jonathan when he starts his Presidency in April 2014. This is a significant time for a new President as we enter a new pricing era, and I have no doubt that Jonathan will provide strong leadership to the ABPI and the industry as a whole.”
We will begin a full programme of media engagement in March 2014 to formally introduce Jonathan as President.
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.